Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ayako Suzuki"'
Publikováno v:
BMC Medical Research Methodology, Vol 23, Iss 1, Pp 1-13 (2023)
Abstract Background Drug toxicity does not affect patients equally; the toxicity may only exert in patients who possess certain attributes of susceptibility to specific drug properties (i.e., drug-host interaction). This concept is crucial for person
Externí odkaz:
https://doaj.org/article/f97507121f574f2594e33342ff48422c
Publikováno v:
Inflammation and Regeneration, Vol 41, Iss 1, Pp 1-15 (2021)
Abstract Even within a single type of cancer, cells of various types exist and play interrelated roles. Each of the individual cells resides in a distinct microenvironment and behaves differently. Such heterogeneity is the most cumbersome nature of c
Externí odkaz:
https://doaj.org/article/7427d50fe5e14dfc8e1677c8fb96676b
Autor:
Soichiro Kakimoto, Morikazu Miyamoto, Takahiro Einama, Yasuhiro Takihata, Hiroko Matsuura, Hideki Iwahashi, Hiroki Ishibashi, Takahiro Sakamoto, Taira Hada, Jin Suminokura, Tsubasa Ito, Rie Suzuki, Ayako Suzuki, Masashi Takano
Publikováno v:
Diagnostic Pathology, Vol 16, Iss 1, Pp 1-10 (2021)
Abstract Background This study aimed to investigate the association between clinicopathologic factors, mesothelin, and cancer antigen (CA) 125 in endometrial carcinoma. Methods Between 1989 and 2017, patients with endometrial carcinoma who underwent
Externí odkaz:
https://doaj.org/article/a062b82e437f4efd9fdc6471798454a2
Autor:
Miho Oka, Liu Xu, Toshihiro Suzuki, Toshiaki Yoshikawa, Hiromi Sakamoto, Hayato Uemura, Akiyasu C. Yoshizawa, Yutaka Suzuki, Tetsuya Nakatsura, Yasushi Ishihama, Ayako Suzuki, Masahide Seki
Publikováno v:
Genome Biology, Vol 22, Iss 1, Pp 1-30 (2021)
Abstract Background Long-read sequencing of full-length cDNAs enables the detection of structures of aberrant splicing isoforms in cancer cells. These isoforms are occasionally translated, presented by HLA molecules, and recognized as neoantigens. Th
Externí odkaz:
https://doaj.org/article/bd383b6712bd4b029623ab9ef02e17ce
Autor:
Daniel C. Beachler, Cynthia de Luise, Aziza Jamal-Allial, Ruihua Yin, Devon H. Taylor, Ayako Suzuki, James H. Lewis, James W. Freston, Stephan Lanes
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)
Abstract Background There is limited real-world safety information on palbociclib for treatment of advanced stage HR+/HER2- breast cancer. Methods We conducted a cohort study of breast cancer patients initiating palbociclib and fulvestrant from Febru
Externí odkaz:
https://doaj.org/article/06e3884409d644d497dcd9497a6e3e71